PD-1 inhibitors offer significant therapeutic benefits for patients with advanced malignancies, including those with bone metastasis, yet they also carry the risk of inducing severe irAEs such as immune thrombocytopenia. Here, PDCD1 is linked to autoimmune thrombocytopenic purpura.